Cytomx Therapeutics Stock News

CytomX Therapeutics Inc. (NASDAQ:CTMX) traded at $3.90 at last check on Tuesday, December 21, made a downward move of -39.49% on its previous days price. Looking at the stock we see that its previous close was $6.45 and the beta (5Y monthly) reads 0.68 with the days price range being $5.89 $6.51. In terms Before You Invest, Make Sure You Check This CytomX Therapeutics Inc. (NASDAQ: CTMX) Analysis Read More »

Investors didn't like the company's preliminary phase 2 results for its experimental cancer therapy.

Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus CytomX Mid-Phase Study Of ADC In Lung And Head & Neck Cancer Patients Show Lackluster Efficacy CytomX

Investors didn't like the company's preliminary phase 2 results for its experimental cancer therapy.

CytomX Therapeutics Inc (NASDAQ: CTMX) announced preliminary Phase 2 results of CX-2029 in patients with either advanced squamous non-small cell lung cancer (sqNSCLC) or head and neck squamous cell

-Objective response rate of 18.8 percent and disease control rate of 87.5 percent in unselected advanced squamous non-small cell lung cancer. Enrollment continues-

CTMX went up 50% since my September coverage but is down to 25% now. They had exciting news about a patent dispute and will present two key misstated datasets in the next 2-3 months.

Virginia Retirement Systems ET AL boosted its holdings in shares of CytomX Therapeutics, Inc. (NASDAQ:CTMX) by 27.7% during the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 150,300 shares of the biotechnology companys stock after buying an additional 32,600 shares during []

Equities research analysts expect CytomX Therapeutics, Inc. (NASDAQ:CTMX) to report ($0.19) earnings per share (EPS) for the current quarter, Zacks reports. Five analysts have provided estimates for CytomX Therapeutics earnings. The lowest EPS estimate is ($0.34) and the highest is $0.29. CytomX Therapeutics reported earnings of ($0.31) per share during the same quarter last year, []

CytomX Therapeutics, Inc. (NASDAQ:CTMX) has been assigned an average rating of Buy from the seven ratings firms that are covering the firm, MarketBeat.com reports. One research analyst has rated the stock with a sell rating, one has issued a hold rating and five have given a buy rating to the company. The average twelve-month price []

CytomX Therapeutics Inc. (NASDAQ:CTMX) concluded the trading at $6.61 on Friday, December 03 with a fall of -4.20% from its closing price on previous day. Taking a look at stock we notice that its last check on previous day was $6.90 and 5Y monthly beta was reading 0.70 with its price kept floating in the CytomX Therapeutics Inc. (CTMX) Recovers 54.44% From Low: Are We There Yet? Read More »

Metropolitan Life Insurance Co NY lifted its holdings in shares of CytomX Therapeutics, Inc. (NASDAQ:CTMX) by 118,175.0% during the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 18,924 shares of the biotechnology companys stock after purchasing an additional 18,908 shares during []

California State Teachers Retirement System trimmed its holdings in shares of CytomX Therapeutics, Inc. (NASDAQ:CTMX) by 3.6% in the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 89,596 shares of the biotechnology companys stock after selling 3,310 shares during the period. []

Investors need to pay close attention to CytomX Therapeutic (CTMX) stock based on the movements in the options market lately.

Equities researchers at BTIG Research assumed coverage on shares of CytomX Therapeutics (NASDAQ:CTMX) in a research note issued to investors on Monday, Price Targets.com reports. The brokerage set a buy rating and a $16.00 price target on the biotechnology companys stock. BTIG Researchs price objective indicates a potential upside of 116.51% from the stocks previous []